AbbVie Inc. (ABBV) Options Risk Score
Real-time risk analysis for ABBV options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full ABBV options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan ABBV Now — Free →
Is it risky to sell options on AbbVie Inc. (ABBV) right now?
Over a 4-week expiry window, AbbVie Inc. (ABBV) scores 100 out of 100 for options catalyst risk (HIGH). What pushes it there: an upcoming earnings report, 9 recent news items, 10 active legal filings and 37 clinical-trial catalysts, all landing inside the 4-week window. Anything at 70 or above counts as HIGH, meaning the premium on ABBV is at least partly compensation for a scheduled event rather than pure time value. It says nothing about direction — only that something is on the calendar.
ABBV shows an IV Rank of 96 — implied volatility is near the top of its own one-year range, so ABBV options are historically expensive, which favours premium-selling strategies, with a current implied volatility of about 35%. IV Rank is the most useful figure for deciding whether to sell or buy premium on ABBV.
ABBV is scheduled to report earnings on 2026-07-31, which falls inside a typical monthly options expiry — expect elevated implied volatility into the event and an IV crush afterward.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer